CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors
Open Access
- 10 April 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1764452
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is regarded as one of the most lethal malignancies, characterized by a poor prognosis and significant resistance to conventional treatments. Although Chimeric Antigen Receptor (CAR)-T cell therapy has been considered to be a revolutionary treatment for B-cell malignancies, its efficacy against solid tumors, including PDAC, has been limited. Nevertheless, after numerous tests pre-clinically and clinically, the acceptance of the first New Drug Application (NDA) for a CAR-T therapy in a solid tumor has sparked considerable hope and interest, which could further accelerate the field. Unlocking the full potential of CAR-T in PDAC requires overcoming significant hurdles, primarily the lack of ideal tumor-specific antigens and the profoundly immunosuppressive tumor microenvironment (TME). Given the shared expression of tumor-associated antigens (TAAs) across diverse solid tumors, this review analyzes promising solid tumor targets to identify candidates with high translational viability for PDAC. We summarize the latest clinical progress of CAR-T cell therapy, highlight emerging therapeutic targets, and explore innovative engineering strategies for developing potent, multi-targeted CAR constructs that are advancing toward future clinical application.Keywords
This publication has 194 references indexed in Scilit:
- Adoptive T‐cell therapies in the clinicBioengineering & Translational Medicine, 2025
- Cytokine release syndrome in solid tumorsCancer, 2025
- Pancreatic Cancer: Pathogenesis and Clinical StudiesMedcomm, 2025
- KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic AdenocarcinomaJAMA Network Open, 2025
- Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal CancerJAMA Oncology, 2024
- Targets of tumor microenvironment for potential drug developmentMedComm – Oncology, 2024
- Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapyBioengineering & Translational Medicine, 2023
- Pancreatic CancerJAMA, 2021
- Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinomaCancer Medicine, 2017
- Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinomaThe Journal of Pathology, 2009